82 related articles for article (PubMed ID: 24577111)
1. Spindle cell squamous carcinoma during BRAF inhibitor therapy for advanced melanoma: an aggressive secondary neoplasm of undetermined biologic potential.
Cohen DN; Lumbang WA; Boyd AS; Sosman JA; Zwerner JP
JAMA Dermatol; 2014 May; 150(5):575-7. PubMed ID: 24577111
[No Abstract] [Full Text] [Related]
2. Eruptive squamous cell carcinomas associated with BRAF-inhibitor therapy in a patient with metastatic melanoma.
Ezra N; Hamid O; Behroozan D
Dermatol Surg; 2012 Jul; 38(7 Pt 1):1086-90. PubMed ID: 22563699
[No Abstract] [Full Text] [Related]
3. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.
Park JJ; Hawryluk EB; Tahan SR; Flaherty K; Kim CC
JAMA Dermatol; 2014 Mar; 150(3):307-11. PubMed ID: 24352115
[TBL] [Abstract][Full Text] [Related]
4. Don't miss the base - keratoacanthoma-type squamous cell carcinoma with perineural invasion during BRAF inhibitor therapy for melanoma.
Schüürmann M; Pönitzsch I; Simon JC; Ziemer M
J Dtsch Dermatol Ges; 2015 Dec; 13(12):1279-81. PubMed ID: 26612802
[No Abstract] [Full Text] [Related]
5. Darier disease-like hyperkeratotic papules and invasive squamous cell carcinoma in a patient with melanoma treated with dabrafenib.
Babuna Kobaner G; Sun GP; Baykal C; Buyukbabani N
Australas J Dermatol; 2018 Aug; 59(3):e231-e233. PubMed ID: 29313899
[No Abstract] [Full Text] [Related]
6. Four times repeated isolated limb infusion with melphalan-controlled locoregional disease in the patient with melanoma of the leg.
El Halabi H; Hijaz F; Gushchin V
Am Surg; 2012 Dec; 78(12):E504-5. PubMed ID: 23265100
[No Abstract] [Full Text] [Related]
7. Successful treatment of invasive squamous cell carcinoma using topical imiquimod.
Hengge UR; Schaller J
Arch Dermatol; 2004 Apr; 140(4):404-6. PubMed ID: 15096367
[No Abstract] [Full Text] [Related]
8. Lupus erythematosus-like skin eruption after vemurafenib therapy.
Reinholz M; Berking C; Hermans C; Ruzicka T; Braun-Falco M
J Am Acad Dermatol; 2014 Oct; 71(4):e159-60. PubMed ID: 25219748
[No Abstract] [Full Text] [Related]
9. Image Gallery: Peculiar subungual localization of a second primary melanoma during BRAF inhibitors treatment for metastatic melanoma: case report.
Ventura A; Pitocco R; Di Stefani A; Cota C; Spallone D; Bianchi L; Spallone G
Br J Dermatol; 2019 May; 180(5):e142. PubMed ID: 31025747
[No Abstract] [Full Text] [Related]
10. A novel treatment approach for extensive, eruptive, cutaneous squamous cell carcinomas in a patient receiving BRAF inhibitor therapy for metastatic melanoma.
Fathi R; Kamalpour L; Gammon B; Tung R
Dermatol Surg; 2013 Feb; 39(2):341-4. PubMed ID: 23227856
[No Abstract] [Full Text] [Related]
11. Treatment of a giant squamous cell carcinoma on the dominant thumb with intralesional 5-fluorouracil.
Reisinger DM; Cognetta AB; Pynes LT; Paredes AA; Sweeney TJ; Dolson DJ
J Am Acad Dermatol; 2011 Jul; 65(1):219-21. PubMed ID: 21679825
[No Abstract] [Full Text] [Related]
12. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
[TBL] [Abstract][Full Text] [Related]
13. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients.
Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Lozano MD; Echeveste JI; Pérez Gracia JL; Alegre E; Carranza O; Zubiri L; Martín-Algarra S; González A
Clin Chim Acta; 2014 Feb; 429():168-74. PubMed ID: 24333389
[TBL] [Abstract][Full Text] [Related]
14. Aspirin use and melanoma: A UCLA pilot study.
Famenini S; Duan L; Young L
J Am Acad Dermatol; 2015 Jun; 72(6):1094-5. PubMed ID: 25981013
[No Abstract] [Full Text] [Related]
15. Basaloid squamous cell carcinoma of the skin.
Boyd AS; Stasko TS; Tang YW
J Am Acad Dermatol; 2011 Jan; 64(1):144-51. PubMed ID: 21167410
[TBL] [Abstract][Full Text] [Related]
16. BRAF and MEK inhibition in melanoma.
Dossett LA; Kudchadkar RR; Zager JS
Expert Opin Drug Saf; 2015 Apr; 14(4):559-70. PubMed ID: 25648338
[TBL] [Abstract][Full Text] [Related]
17. Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients.
Mochel MC; Hammond MR; Frederick DT; Alora-Palli MB; Piris A; Flaherty KT; Hoang MP
J Am Acad Dermatol; 2015 Sep; 73(3):491-9.e2. PubMed ID: 26190239
[TBL] [Abstract][Full Text] [Related]
18. Multiple BRAF Wild-Type Melanomas During Dabrafenib Treatment for Metastatic BRAF-Mutant Melanoma.
Carrera C; Puig-Butillè JA; Tell-Marti G; García A; Badenas C; Alós L; Puig S; Malvehy J
JAMA Dermatol; 2015 May; 151(5):544-8. PubMed ID: 25651238
[TBL] [Abstract][Full Text] [Related]
19. Squamoproliferative skin lesion during braf inhibitors:one size does not fit all.
Mandalà M; Gianatti A; Massi D
J Eur Acad Dermatol Venereol; 2014 Mar; 28(3):389-91. PubMed ID: 23763655
[No Abstract] [Full Text] [Related]
20. Squamous cell carcinoma arising in a split-thickness skin graft donor site.
Haik J; Georgiou I; Farber N; Volkov A; Winkler E
Burns; 2008 Sep; 34(6):891-3. PubMed ID: 17869430
[No Abstract] [Full Text] [Related]
[Next] [New Search]
